Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1477)

VOLUNTARY ANNOUNCEMENT
PRIMARY CLINICAL ENDPOINT ACHIEVED IN THE PHASE III CLINICAL TRIAL OF OT-1001

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the "**Board**") of directors of the Company is pleased to announce that the phase III clinical trial of OT-1001 (ZERVIATE), a potent and highly selective histamine-1 receptor antagonist with anti-allergic properties, has achieved its primary clinical endpoint and received positive results.

OT-1001 (ZERVIATE) was developed by Nicox Ophthalmics, Inc. ("**Nicox**"). OT-1001 is the first and only eye drop formulation of the antihistamine cetirizine, the active ingredient in ZYRTEC®, and is currently commercialized in the United States for ocular itching associated with allergic conjunctivitis. Studies have shown that OT-1001 is a safe and effective antihistamine therapeutic agent. OT-1001 has a rapid onset of action, and the effect is able to last for at least 8 hours after administration. OT-1001 covers a wide range of patients. In addition to treating adult patients, the safety and effectiveness of OT-1001 has been established in pediatric patients two years of age and older, therefore meeting the current clinical needs of treating pediatric patients with allergic conjunctivitis. The Group obtained an exclusive license from Nicox to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell (or otherwise commercialize) OT-1001 (ZERVIATE) in the Greater China region in March 2019, and extended the exclusive rights to 11 countries in Southeast Asia in March 2020. In December 2020, the first patient has been successfully enrolled and dosed in the phase III clinical trial of OT-1001 in China.

The phase III clinical trial of OT-1001 was designed as a randomized, observer-masked, positive control, multi-center parallel clinical trial to evaluate the safety and efficacy of the cetirizine hydrochloride ophthalmic solution of 0.24% concentration in comparison with emedastine difumarate ophthalmic solution of 0.05% concentration for Chinese patients with allergic conjunctivitis. A total of 296 patients were randomized across multiple clinical sites in China. OT-1001 was found to be non-inferior to emedastine difumarate in the primary efficacy endpoint of change from baseline in the itching score in the 24 hours prior to the Day 14 visit. OT-1001 was safe and well-tolerated with no difference in the proportion of patients with adverse events compared to emedastine difumarate. The successful completion of this clinical trial is an important step towards commercialization of OT-1001.

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-1001 (ZERVIATE) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, March 2, 2022

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE and Mr. Yiran HUANG as independent non-executive directors.